Deucravacitinib (Sotyktu)

Deucravacitinib is a tablet approved in the United States in 2022 for moderate to severe plaque psoriasis in adults who need treatment that works throughout the body. It is not a biologic. Biologics are large proteins grown in living cells, which is why adalimumab and risankizumab have to be injected. Deucravacitinib is a small molecule made by chemistry, small enough to survive the stomach and be absorbed. A biologic intercepts the inflammation signal outside the cell; this drug works inside it, on the machinery that passes the signal along.

When a signal such as interleukin-23 lands on an immune cell, the message must be relayed to the nucleus before anything happens. Enzymes called JAKs and TYK2 do the relaying. Deucravacitinib blocks TYK2, so those messages, including the interleukin-23 signal that drives psoriasis, stop being passed on.

What makes it unusual is where it binds. Most drugs in this family sit in the working part of the enzyme, shared across all JAKs, which is why they also affect signals unrelated to psoriasis. Deucravacitinib binds a separate regulatory part of TYK2, shaped differently there than in JAK1, JAK2 and JAK3, so the block is far more selective.

That selectivity is the practical point. Its label does not carry the boxed warning about serious infections, cancer, blood clots and cardiovascular death that the JAK inhibitors carry. It still damps down part of the immune response, so infections, cold sores and mouth ulcers come up most, and it is newer than the treatments it competes with.

Completely clear skin, for most people | Biologics clear more, on average: Most people get a large improvement rather than complete clearance. If clear skin is the goal, the injected biologics reach it more often.

One form only:

The tablet is swallowed whole:

Storage:

One strength only, so no ladder to climb and no dose to build up to.

Dosing is as simple as it gets for a systemic drug. No loading dose, no build-up, no weight adjustment.

When to take it: Once a day, at whatever time suits you, with or without food. Pick one time and keep to it, because a daily tablet is easy to lose track of in a way a fortnightly injection is not. Attaching it to something you already do, like brushing your teeth at night, works better than intending to remember. Swallow the tablet whole with water. Do not crush, split or chew it. If it upsets your stomach, take it with a meal.

If you miss a dose: Take it as soon as you remember on the same day. If you do not remember until the next day, skip it and take that day's tablet as usual. Never take two in one day. Missing the occasional dose will not undo months of progress, but repeatedly missing them is one of the commonest reasons a treatment looks like it has stopped working.

Everyone is screened for tuberculosis before starting, with a skin test or a TB blood test, and a chest X-ray if positive. Dormant TB is treated first. This applies even though it is a tablet rather than an injected biologic.

Hepatitis B and C are usually checked at the same time.

Liver blood tests are often checked before starting and again if there is a reason to. Some people show a rise in creatine kinase, a muscle enzyme, or in triglycerides, so those may be looked at too. There is no rigid schedule like methotrexate's; how often anything is repeated is your doctor's judgment.

The rest is clinical. Report repeated infections, cold sores that keep coming back, mouth ulcers that will not heal, and unexplained muscle pain. Skin should be checked periodically, as on any drug that damps down the immune response.

There is no taper and no withdrawal reaction. Stopping does not cause the sudden severe flare that stopping oral steroids can. The drug clears within days, so psoriasis returns sooner than after stopping an injected biologic, usually over several weeks to a couple of months. Restarting generally works. Because it is a small molecule rather than an antibody, the body does not build antibodies against it during a break, a real advantage over the injected drugs if you need to stop for a while.

Brand only. There is no generic and will not be for years, so there is no cheaper equivalent. The list price is high, in the same range as the injected biologics over a year, which surprises people who assume a tablet must be cheaper. Almost nobody pays it. What matters is what your plan does, and approval takes paperwork. Prior authorization is close to universal, and most plans want documented failure of something cheaper first: phototherapy, methotrexate or apremilast. Manufacturer copay cards can bring the monthly cost down to very little on commercial insurance. By law they cannot be used with Medicare or Medicaid. For those plans, or no insurance, the manufacturer's patient assistance program and independent foundations are the usual routes, and the rules change regularly. One thing in its favor on cost: no infusion visits, no injection training, no cold chain, so the costs around the drug are lower even when the drug is not.

• "It is a JAK inhibitor, so it has the same warnings." It works on a related enzyme, but binds a different part of it and is far more selective. Its label does not carry the boxed warning about serious infections, cancer, blood clots and cardiovascular death that the JAK inhibitors carry. A fair question, honestly answered.
• "It is a steroid." It is not. Steroids act broadly and cause weight gain, thinning skin and a rebound flare when stopped. This blocks one relay enzyme, and stopping it causes no rebound.
• "A pill cannot work as well as a shot." Too absolute. It clears skin for a lot of people. On average the injected biologics clear more completely, a real difference worth weighing.
• "I will need constant blood tests." Not the way methotrexate requires. Tuberculosis and hepatitis are checked before starting, liver tests usually too, and after that testing follows your situation, not a fixed calendar.
• "If it works I can take it only when I flare." It is a daily maintenance drug. Intermittent use gives up most of the benefit and makes the response impossible to judge.

1. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. Journal of the American Academy of Dermatology. 2023. — Journal of the American Academy of Dermatology, 2023
2. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. Journal of the American Academy of Dermatology. 2023. — Journal of the American Academy of Dermatology, 2023
3. Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane database of systematic reviews. 2025. — The Cochrane database of systematic reviews, 2025
4. Tsai TF, Tada Y, Kung C, et al. Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis. The Journal of dermatology. 2024. — The Journal of dermatology, 2024
5. Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.). 2023. — Arthritis & rheumatology (Hoboken, N.J.), 2023